Table II.
Echocardiographic and cardiac MRI abnormalities indicative of mRNA COVID-19 VAM (n = 29)
| Abnormalities | Number of institutions, n (%) |
|---|---|
| Echocardiography | |
| Diminished ventricular function (global) | 27 (93%) |
| Regional wall motion abnormality | 5 (17%) |
| Abnormal strain imaging | 3 (10%) |
| Pericardial effusion | 21 (72%) |
| Atrioventricular valve regurgitation | 8 (28%) |
| Diastolic dysfunction | 3 (10%) |
| Coronary artery dilation | 2 (7%) |
| Cardiac MRI | |
| Late gadolinium enhancement | 29 (100%) |
| Myocardial edema | 28 (96%) |
| Pericardial effusion | 22 (76%) |
MRI, magnetic resonance imaging.
In total, 75% of institutions considered a combination of late gadolinium enhancement, myocardial edema, and pericardial effusion to be diagnostic of mRNA COVID-19 VAM.